Next Article in Journal
Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline
Previous Article in Journal
Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes
 
 
Article
Peer-Review Record

Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience

Curr. Oncol. 2022, 29(1), 221-230; https://doi.org/10.3390/curroncol29010021
by Michael C. Tjong 1, Malavan Ragulojan 2, Ian Poon 1,*, Alexander V. Louie 1, Susanna Y. Cheng 3, Mark Doherty 3, Liying Zhang 1, Yee Ung 1, Patrick Cheung 1 and Parneet K. Cheema 4,*
Reviewer 1: Anonymous
Curr. Oncol. 2022, 29(1), 221-230; https://doi.org/10.3390/curroncol29010021
Submission received: 7 November 2021 / Revised: 4 January 2022 / Accepted: 5 January 2022 / Published: 7 January 2022
(This article belongs to the Section Thoracic Oncology)

Round 1

Reviewer 1 Report

Dear authors,

I thank you for your interesting manuscript. Please find my comment here under: 

1) Were the duration of toxicities different in interval 1 & 2? Would you please report, if possible, show data?

2) How about RT technical data? Many institutes choose for some more sophisticated RT planning, even for 1x8 Gy spine metastase, such as VMAT than 3D, 2D planning in the case of combination with or close administration of ICIs. Would you please RT technics in your study group? Were some different between interval 1 & 2 in the term of RT technic?

3) Would you please report the dose level in intracranial group? There were just few patients in this group, all in ablation dose level?

4) Can you please report steroid used after RT in your study group?

5) If possible, please report eventually delay in treatment schedule especially in interval 1. For example because of steroid dependency, toxicities or performance status after RT or ICIs.

6) If possible, add in title : a single institute or retrospective cohort study.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

 

The paper is of great interest because association of ICI and radiotherapy is more and more common; it is original, the subject is relevant for therapeutic options in advanced NSCLC and provides interesting results about time of radiation and Ici therapy. Larger series, a distinction of different radiation dose, sites treated and number of irradiated areas might be helpful to further understand mechanisms of correlation between ICI and radiation. Conclusions are well written and consistent with results of the paper. References are adequate and i do not have more comments regarding figures and tables which area easy to understand and sufficient to describe their work.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop